Recombinant Human Type-5 Adenovirus
Trade name: Gendicine
Biologicalexperimental
Clinical trial activity
11 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Oct 31, 2016 (NCT03790059)
Timeline
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06919848 | Phase 2 | May 1, 2025 | Fudan University |
| NCT06196671 | Phase 2 | Dec 1, 2024 | Fudan University |
| NCT06685354 | Phase 2 | Nov 30, 2024 | Henan Medical University |
| NCT05823987 | Phase 2 | May 16, 2023 | Fudan University |
| NCT05675462 | Phase 1 | Mar 1, 2023 | Fudan University |
| NCT05564897 | Phase 2 | Aug 26, 2022 | Chinese Academy of Medical Sciences |
| NCT05303844 | Phase 1 | Apr 2, 2022 | Fudan University |
| NCT05303090 | Phase 1 | Mar 31, 2022 | Fudan University |
| NCT05051696 | N/A | Sep 26, 2021 | Jiao Tong University |
| NCT03780049 | Phase 3 | Oct 1, 2018 | Sun Yat-Sen University |
| NCT03790059 | N/A | Oct 31, 2016 | Institute of hepatobiliary surgery,Southwest Hospital, People's Liberation Army of China |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fudan University | Academic/Hospital | 6 | 6 | 2 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Institute of hepatobiliary surgery,Southwest Hospital | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2016 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2018 |
7 organizations
Page 1 / 1